BioSpace News Archive

DNA Script, a pioneer in Enzymatic DNA Synthesis for on-demand DNA printing, announced the completion of its Series C financing, raising $200 million of new capital.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the H.C. Wainwright BIOCONNECT Conference, being held virtually from January 10-13, 2022.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET.

The real world evidence solutions market has been projected to grow at a noticeable speed in the years to come.

A suction catheter is a medical device used to extract bodily secretions, such as mucus or saliva from the upper airway. A suction catheter connects to a suction machine or collection canister.

A master patient index software (MPI) refers to patient master index, patient registry, and client registry. It is an electronic database system that holds demographic patient information.

Leucovorin calcium is an active metabolite of folic acid. Leucovorin calcium aids in providing a counteract effect on the toxic medications, thereby protecting the patient while enabling the antitumor activity of the folate antagonist.

Radiofrequency ablation (also known as RFA or Barrx) is a technique that allows for a controlled superficial burn of the gastrointestinal tract lining to eliminate abnormal tissue.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global Th17 driven disease treatment market is anticipated to register strong growth between 2020 and 2030.

UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, biotechnology company focused on immunology and infectious diseases, announced that the first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis.